Cargando…
The Anticancer Peptide TAT-RasGAP(317−326) Exerts Broad Antimicrobial Activity
Antibiotic resistance has become a major health issue. Nosocomial infections and the prevalence of resistant pathogenic bacterial strains are rising steadily. Therefore, there is an urgent need to develop new classes of antibiotics effective on multi-resistant nosocomial pathogenic bacteria. We have...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461357/ https://www.ncbi.nlm.nih.gov/pubmed/28638371 http://dx.doi.org/10.3389/fmicb.2017.00994 |
_version_ | 1783242325765390336 |
---|---|
author | Heulot, Mathieu Jacquier, Nicolas Aeby, Sébastien Le Roy, Didier Roger, Thierry Trofimenko, Evgeniya Barras, David Greub, Gilbert Widmann, Christian |
author_facet | Heulot, Mathieu Jacquier, Nicolas Aeby, Sébastien Le Roy, Didier Roger, Thierry Trofimenko, Evgeniya Barras, David Greub, Gilbert Widmann, Christian |
author_sort | Heulot, Mathieu |
collection | PubMed |
description | Antibiotic resistance has become a major health issue. Nosocomial infections and the prevalence of resistant pathogenic bacterial strains are rising steadily. Therefore, there is an urgent need to develop new classes of antibiotics effective on multi-resistant nosocomial pathogenic bacteria. We have previously shown that a cell-permeable peptide derived from the p120 Ras GTPase-activating protein (RasGAP), called TAT-RasGAP(317−326), induces cancer cell death, inhibits metastatic progression, and sensitizes tumor cells to various anti-cancer treatments in vitro and in vivo. We here report that TAT-RasGAP(317−326) also possesses antimicrobial activity. In vitro, TAT-RasGAP(317−326), but not mutated or truncated forms of the peptide, efficiently killed a series of bacteria including Escherichia coli, Acinetobacter baumannii, Staphylococcus aureus, and Pseudomonas aeruginosa. In vivo experiments revealed that TAT-RasGAP(317−326) protects mice from lethal E. coli-induced peritonitis if administrated locally at the onset of infection. However, the protective effect was lost when treatment was delayed, likely due to rapid clearance and inadequate biodistribution of the peptide. Peptide modifications might overcome these shortcomings to increase the in vivo efficacy of the compound in the context of the currently limited antimicrobial options. |
format | Online Article Text |
id | pubmed-5461357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-54613572017-06-21 The Anticancer Peptide TAT-RasGAP(317−326) Exerts Broad Antimicrobial Activity Heulot, Mathieu Jacquier, Nicolas Aeby, Sébastien Le Roy, Didier Roger, Thierry Trofimenko, Evgeniya Barras, David Greub, Gilbert Widmann, Christian Front Microbiol Microbiology Antibiotic resistance has become a major health issue. Nosocomial infections and the prevalence of resistant pathogenic bacterial strains are rising steadily. Therefore, there is an urgent need to develop new classes of antibiotics effective on multi-resistant nosocomial pathogenic bacteria. We have previously shown that a cell-permeable peptide derived from the p120 Ras GTPase-activating protein (RasGAP), called TAT-RasGAP(317−326), induces cancer cell death, inhibits metastatic progression, and sensitizes tumor cells to various anti-cancer treatments in vitro and in vivo. We here report that TAT-RasGAP(317−326) also possesses antimicrobial activity. In vitro, TAT-RasGAP(317−326), but not mutated or truncated forms of the peptide, efficiently killed a series of bacteria including Escherichia coli, Acinetobacter baumannii, Staphylococcus aureus, and Pseudomonas aeruginosa. In vivo experiments revealed that TAT-RasGAP(317−326) protects mice from lethal E. coli-induced peritonitis if administrated locally at the onset of infection. However, the protective effect was lost when treatment was delayed, likely due to rapid clearance and inadequate biodistribution of the peptide. Peptide modifications might overcome these shortcomings to increase the in vivo efficacy of the compound in the context of the currently limited antimicrobial options. Frontiers Media S.A. 2017-06-07 /pmc/articles/PMC5461357/ /pubmed/28638371 http://dx.doi.org/10.3389/fmicb.2017.00994 Text en Copyright © 2017 Heulot, Jacquier, Aeby, Le Roy, Roger, Trofimenko, Barras, Greub and Widmann. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Heulot, Mathieu Jacquier, Nicolas Aeby, Sébastien Le Roy, Didier Roger, Thierry Trofimenko, Evgeniya Barras, David Greub, Gilbert Widmann, Christian The Anticancer Peptide TAT-RasGAP(317−326) Exerts Broad Antimicrobial Activity |
title | The Anticancer Peptide TAT-RasGAP(317−326) Exerts Broad Antimicrobial Activity |
title_full | The Anticancer Peptide TAT-RasGAP(317−326) Exerts Broad Antimicrobial Activity |
title_fullStr | The Anticancer Peptide TAT-RasGAP(317−326) Exerts Broad Antimicrobial Activity |
title_full_unstemmed | The Anticancer Peptide TAT-RasGAP(317−326) Exerts Broad Antimicrobial Activity |
title_short | The Anticancer Peptide TAT-RasGAP(317−326) Exerts Broad Antimicrobial Activity |
title_sort | anticancer peptide tat-rasgap(317−326) exerts broad antimicrobial activity |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461357/ https://www.ncbi.nlm.nih.gov/pubmed/28638371 http://dx.doi.org/10.3389/fmicb.2017.00994 |
work_keys_str_mv | AT heulotmathieu theanticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT jacquiernicolas theanticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT aebysebastien theanticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT leroydidier theanticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT rogerthierry theanticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT trofimenkoevgeniya theanticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT barrasdavid theanticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT greubgilbert theanticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT widmannchristian theanticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT heulotmathieu anticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT jacquiernicolas anticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT aebysebastien anticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT leroydidier anticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT rogerthierry anticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT trofimenkoevgeniya anticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT barrasdavid anticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT greubgilbert anticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity AT widmannchristian anticancerpeptidetatrasgap317326exertsbroadantimicrobialactivity |